Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.70 |
| ▸ | CACNA1D | Q01668 | 9/20 | 0.65 |
| ▸ | CACNA1F | O60840 | 8/20 | 0.65 |
| ▸ | CACNA1S | Q13698 | 8/20 | 0.65 |
| ▸ | CACNA1C | Q13936 | 8/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3027412 | 0.87 | ADORA3 (0.89) | ADORA3CACNA1DCACNA1FCACNA1SCACNA1C | |
| SCHEMBL7267796 | 0.86 | CACNA1F (0.57) | ADORA3CACNA1DCACNA1FCACNA1SCACNA1C | |
| SCHEMBL11819548 | 0.85 | CACNA1F (0.69) | ADORA3CACNA1DCACNA1FCACNA1SCACNA1C | |
| SCHEMBL11778345 | 0.84 | CACNA1F (0.67) | ADORA3CACNA1DCACNA1FCACNA1SCACNA1C | |
| SCHEMBL11785984 | 0.84 | KDM4E (0.70) | ADORA3CACNA1DCACNA1FCACNA1SCACNA1C | |
| SCHEMBL29173863 | 0.83 | ADORA3 (0.82) | ADORA3CACNA1DCACNA1FCACNA1SCACNA1C | |
| SCHEMBL1664685 | 0.83 | ADORA3 (0.71) | ADORA3CACNA1DCACNA1FCACNA1SCACNA1C | |
| SCHEMBL3032551 | 0.83 | CACNA1F (0.66) | ADORA3CACNA1DCACNA1FCACNA1SCACNA1C | |
| SCHEMBL3016370 | 0.83 | CACNA1F (0.66) | ADORA3CACNA1DCACNA1FCACNA1SCACNA1C | |
| SCHEMBL3026966 | 0.83 | ABCC1 (0.71) | ADORA3CACNA1DCACNA1FCACNA1SCACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045428-B2 | Substituted heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2015-06-02 | — | — | US | claimed |
| US-8716319-B2 | Substituted heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2014-05-06 | — | — | US | claimed |
| US-20130324525-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-12-05 | — | — | US | claimed |
| US-9045428-B2 | Substituted heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-8716319-B2 | Substituted heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20130324525-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-12-05 | — | — | US | disclosed |
| US-20100197684-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | GILEAD PALO ALTO, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-20090181986-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | CV THERAPEUTICS, INC. | 2009-07-16 | — | — | US | disclosed |
| US-20090012103-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197684-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | NQO1, GPR119, GLP1R | ADORA3 829/4885CACNA1D 1917/4885CACNA1F 2931/4885 |
| US-20130324525-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | NQO1, GPR119, GLP1R | ADORA3 829/4885CACNA1D 1917/4885CACNA1F 2931/4885 |
| US-20090181986-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | NQO1, GPR119, GLP1R | ADORA3 829/4885CACNA1D 1917/4885CACNA1F 2931/4885 |
| US-20090012103-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | NQO1, GPR119, GLP1R | ADORA3 829/4885CACNA1D 1917/4885CACNA1F 2931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.